₨ 28,500.00
MBBS
Erbitux Injection 100 mg 1 Vial
- Does this requires a prescription ? Yes
- Generic Name: Cetuximab
- Manufactured by : Martin Dow Marker
- Drug Strength : 100 mg
- Drug Form : Injection
- Pack Size : 1 vial
- Product SKU : pg_7719_10714
Erbitux Injection contains Cetuximab | belongs to Monoclonal antibody
How it works
Erbitux Injection 100 mg 1 Vial by preventing the growth and spread of cancer cells in the body.
Side effects
Major & minor side effects for Erbitux Injection 100 mg 1 Vial
- Nausea and vomiting
- Diarrhea
- Skin Reactions severe
- Headache
- Low magnesium levels
- Infections severe
- Dizziness
- Cough
- Unusual tiredness or weakness
Uses of Erbitux Injection 100 mg 1 Vial
What is it prescribed for?
-
Colorectal Cancer
This medicine is used in the treatment of cancer that affects the colon and rectum.
-
Head and Neck Cancer
This medicine is used in the treatment of cancer that affects the head and neck.
Concerns
Frequently asked questions
-
Onset of action
The amount of time required for this medicine to show its action is not clinically established.
-
Duration of Effect
The amount of time for which this medicine remains active in the body is not clinically established.
-
Safe with Alchohol?
Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
-
Is it habit forming?
No habit-forming tendencies were reported.
-
Usage in pregnancy?
This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.
-
Usage while breast-feeding?
This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue breastfeeding for a specific period of time or prescribe an alternative medicine based on your clinical condition.
When not to use?
-
Allergy
This medicine is not recommended for use in patients with a known allergy to Erbitux Injection 100 mg 1 Vial or any other inactive ingredients present along with it.
Warnings
-
Pregnancy
This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.
-
Breast-feeding
This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue breastfeeding for a specific period of time or prescribe an alternative medicine based on your clinical condition.
-
Infusion related reactions
This medicine has been associated with severe infusion-related reactions, characterized by symptoms such as fever, chills, rigors, low blood pressure, hives, swelling, etc. The onset of these reactions usually ranges from 30 minutes to 2 hours after starting the first intravenous infusion. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary in some cases based on the clinical condition of the patient.
-
Skin reactions
Use of this medicine may increase the risk of severe skin reactions. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary in some cases based on the clinical condition of the patient. Treatment may be discontinued in case of severe skin reactions.
-
Infections
This medicine should be used with caution due to the increased risk of severe and potentially life-threatening infections occurring due to bone marrow suppression. Report any unusual symptoms such as a fever, diarrhea, sore throat, pain or burning during urination, etc. to the doctor immediately. Close monitoring of clinical condition, dose adjustments, or replacement with a suitable alternative may be necessary in some cases.
-
Electrolyte disturbances
This medicine should be used with caution due to the increased risk of electrolyte depletion especially magnesium levels. Decreased Potassium and Calcium levels have also been reported with this medicine. Close monitoring of clinical condition, appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary in some cases.
-
Lung toxicity
This medicine may increase the risk of toxic effects on the lungs and could lead to respiratory failure. The lung toxicity is dose-related and close monitoring of lung function is recommended during the therapy with this medicine. Any symptoms of lung toxicity should be informed to the doctor on priority. The treatment should be discontinued if such symptoms appear.
-
Cardiovascular disorders
This medicine should be used with extreme caution in patients suffering from diseases of the heart due to the increased risk of worsening of the patient's condition. Close monitoring of heart function and vital signs is recommended for such patients. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition.
-
Eye disorders
This medicine should be used with extreme caution in patients with eye disorders due to the increased risk of worsening of the patient's condition. Close monitoring is recommended for such patients. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition.
-
Use in Children
This medicine is not recommended for use in patients below 18 years of age since the safety and efficacy of use are not clinically established.
-
Contraception
Use of this medicine may increase the risk of harm to the unborn baby in pregnant women. Effective contraception is advised for the women with the childbearing potential to avoid such risks. Birth controls should be administered while receiving this medicine and for 2 months post-therapy to prevent the pregnancy.
Dosage
-
Missed Dose
This medicine is usually given in a clinical setting so the likelihood of missing a dose is very less. If you miss any chemotherapy session you should contact your doctor immediately and fix an appointment as recommended by your doctor.
-
Overdose
Since this medicine is administered in the hospital or clinical setting by a qualified healthcare professional, the likelihood of an overdose is very low. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.
Interactions
Interaction with Medicines- Thalidomide severe
- Proton pump inhibitors moderate
- Fluorouracil moderate
- Cisplatin moderate
-
severe
This medicine should be used with extreme caution in patients suffering from diseases of the heart due to the increased risk of worsening of the patient's condition. Close monitoring of heart function and vital signs is recommended for such patients. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition.
-
severe
This medicine should be used with extreme caution in patients suffering from diseases of the skin due to the increased risk of worsening of the patient's condition. Close monitoring is recommended for such patients. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition.
-
severe
This medicine should be used with extreme caution in patients with eye disorders due to the increased risk of worsening of the patient's condition. Close monitoring is recommended for such patients. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition. Treatment may be discontinued if the eye disorders worsen.
-
severe
This medicine should be used with caution in patients with a history of interstitial lung disease presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation due to the increased risk of the lung toxicity. Appropriate dose adjustments and frequent clinical monitoring are advised in such cases. An alternative treatment option should be considered in some cases based on the clinical condition.
-
moderate
This medicine should be used with caution in patients with severe renal dysfunction due to increased risk of worsening of the condition. Close monitoring of renal function, appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.
-
severe
This medicine should be used with caution due to the increased risk of electrolyte depletion especially magnesium levels. Decreased Potassium and Calcium levels have also been reported with this medicine. Close monitoring of clinical condition, appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary in some cases based on the clinical condition.
General Instructions
This medicine is usually administered by a qualified healthcare professional in the hospital or clinical setting. Inform the doctor if you have a known history of allergy to this medicine. Report to the doctor all your current medicines including any herbs and supplements as well as your medical conditions before receiving this medicine. Any signs and symptoms of heart and lung dysfunction should be reported to the doctor on priority.
Other details
- Usage does not depend on food timings
- To be taken as instructed by doctor
- May cause sleepiness
References
- dailymed - cetuximab [Internet]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9 [cited 2/1/2021]. 2020
How to use Erbitux Injection 100 mg 1 Vial
Do not administer as an IV push or bolus. Administered via infusion pump or syringe pump. Administer initial dose over 120 min, then administer subsequent dose over 60 min. The maximum inf rate is 5 mL/min (10 mg/min). Administer cetuximab through a low protein-binding 0.22 micrometer in-line filter. Observe patient for 1 hour after administration. Flush lines with 0.9 % NaCl injection after IV injection.
Stability: Store vials under refrigeration at 2°C-8°C (36°F-46°F). Do not freeze. Preparations of cetuximab in infusion containers are chemically and physically stable for up to 12 hours at 2°C-8°C (36°F-46°F) and up to 8 hours at controlled room temperature 20°C-25°C (68°F-77°F). Discard any remaining solution in the infusion container after 8 hours at controlled room temperature or after 12 hours at 2°C-8°C (36°F-46°F). Discard any unused portion of the vial.
what are the adverse effects of Erbitux Injection 100 mg 1 Vial?
Skin reactions, hypomagnesaemia, mild or moderate infusion-related reactions. Mild or moderate mucositis leading to epistaxis. Increased liver enzyme levels. Headache, conjunctivitis, diarrhoea, nausea, vomiting, fatigue, dehydration in particular secondary to diarrhoea or mucositis, hypocalcaemia, anorexia.
What happens if I miss a dose of Erbitux Injection 100 mg 1 Vial?
Metastatic colorectal carcinoma: Adults: Initial: 400 mg/m² IV infusion over 120 min. Maintenance: 250 mg/m² IV infusion over 60 min once weekly. Max Infusion Rate: 5 mL/min. Children: Not recommended.
One of the following licensed pharmacy from the nearest location will deliver Erbitux Injection 100 mg 1 Vial. The details of the licensed pharmacy shall be shared once you request the drugs and the respective pharmacy accepts your request based on valid prescription and availability.
Questions and Answers
There are no questions yet. Be the first to ask a question about this product.
Related products
Products listed on medicalstore.com.pk are 100% genuine and sourced from licensed pharmacies.
We work hard to bring you unimaginable discounts without compromising on quality.
We uses SSL (standard security technology) to ensure data privacy of all our customers.
Reviews
There are no reviews yet.